Diasorin’s Post

At Endogena Therapeutics, Inc., we are revolutionizing treatment for retinal diseases! Check out our recent publication to learn how we used a single #smallmolecule to restore vision in a mouse model of retinal degeneration. #scientificresearch #regenerativemedicine #stemcells #drugdiscovery #clinicaltrials

🔬Citation Break!📖 This citation investigates the relationship between Beta-Amyloid peptides and extracellular vesicles (EVs). The researchers wish to show how forms of Aβ might travel throughout the body, and how this process might be involved in the pathology of Alzheimer's Disease. Several rPeptide products were used for the authors’ experiments, SIMOA assays, and other analyses during their research: Beta-Amyloid (1-40) and (1-42) NaOH (A-1155 and A-1165) and sequence scrambled versions of each (A-1003 and A-1004). Paper: https://t.ly/b0LFC Beta-Amyloid Products: https://t.ly/w-f7N #Research #Development #rPeptide #Alzheimers #Experiment #NaOH #Scrambled #BetaAmyloid

From targeted therapy for intracranial hemorrhage to multimodal endoscopic tattoo inks for precise marking of gastrointestinal lesions, today’s ABRC conference confirms that translational research is alive and well in #Arizona! I am impressed with the variety of research presentations and the more than 75 (!) poster presentations. From bench to bedside, the future of Arizona #bioscience looks very bright. #PHXisBIO #biosciences

I hardly celebrate papers but this is special: have a look to our new work exploiting Membrane Sensing Peptides for Extracellular Vesicles direct analysis - just published in Advanced Science Wiley: https://lnkd.in/d8ZJCUHy Highlights: - we show that the integration of #MSP and Single Molecule Array (#SIMOA®) technology enables direct EV analysis in blood samples with no requested pre-isolation steps - we provide evidence that MSP act as general and pan-vesicular EV binders, not introducing biases due to the pre-enrichment of specific EV subpopulations - we show that MSP expand EV profiling beyond tetraspanin-responsive EV populations, enabling the analysis of EVs and EV mimics that lack the “canonical” expression of commonly used CD9/CD63/CD81 markers - we demonstrate the possibility for clinical translation in analysing an EV-associated markers signature in patients stratification (myocardial infarction vs stable angina) And much more…  😉 A great Team and collaborative effort – thanks to all involved ! Marina Cretich, Roberto Frigerio, Greta Bergamaschi, Paola Gagni, Annalisa Radeghieri, Lucio Barile, Quanterix

A fascinating paper explaining the multi-faceted benefits of Profhilo - have a read!

I am pleased to announce that the research conducted during my tenure in Dr. Nikolaos G. Frangogiannis' lab has been published in the esteemed journal "Circulation Research". This accomplishment represents a significant contribution to the field, and I am honored to share it with the scientific community. Our study delves into the endogenous mechanisms that negatively regulate the TGF-β response, protecting the pressure-overloaded heart from progressive fibrosis and adverse remodeling. Specifically, we provide new insights into how the antifibrotic effects of Smad7 in the pressure-overloaded heart not only reduce collagen deposition but also suppress MMP2-mediated matrix denaturation. Additionally, we demonstrate the paracrine effects of Smad7 that inhibit macrophage activation through suppression of matricellular proteins. This achievement was made possible through the unwavering support and collaboration of my esteemed colleagues and mentor, Dr. Frangogiannis. You can access the full paper here: https://lnkd.in/eSRUhxjC I look forward to continuing to bridge the gap between academia and industry, contributing to advancements in biotech and precision medicine. Thank you all for your support! #Research #Biotech #PrecisionMedicine #ScientificBreakthroughs #CirculationResearch

How can the platform business model transform the way healthcare is delivered, and what implications does this transformation have on laboratory medicine and pathology? Listen to Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, and Bill Morice, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, discuss how the platform model is being used in the healthcare industry to drive innovation and reimagine how care is provided. https://bit.ly/4bb9Kzd

𝗧𝗵𝗲 𝗴𝘂𝘆𝘀 𝗵𝗮𝘃𝗲 𝗴𝗮𝘁𝗵𝗲𝗿𝗲𝗱 𝘀𝗼𝗺𝗲 𝗽𝗿𝗶𝗻𝗰𝗶𝗽𝗹𝗲𝘀 𝗮𝗻𝗱 𝗯𝘂𝗶𝗹𝘁 𝗮 𝗹𝗼𝗴𝗶𝗰 𝗳𝗼𝗿 𝘀𝗲𝗹𝗲𝗰𝘁𝗶𝗻𝗴 𝗯𝗶𝗼𝗺𝗮𝗿𝗸𝗲𝗿𝘀 𝗳𝗼𝗿 𝗮 𝗰𝗲𝗿𝘁𝗮𝗶𝗻 𝗰𝗮𝗻𝗰𝗲𝗿 𝗻𝗼𝘀𝗼𝗹𝗼𝗴𝘆. If this logic is the basis for LIMS, it could be a compromise between two aspirations: to make medicine a craft with clear rules and the reluctance of the physician, with his art and experience, to follow outside laboratory guidelines. Creating shared rules for test prescribing can help in many controversial cases - https://lnkd.in/g-tWxcdF #ADLM #CanserNosology #LIMS #VivicaLIMS #LifeDataLab https://about.vivica.us https://lifedl.net

Flow cytometry allows researchers to examine and characterize thousands of cells quickly, by detecting unique properties such as size, complexity, and biomarker expression. Its ability to swiftly generate high-dimensional data sets and facilitate cell sorting based on specific markers continues to redefine our understanding of cellular behavior and holds promise for groundbreaking advancements in diagnostics, therapeutics, and fundamental research in immunology, oncology, microbiology, and beyond. Have you been enjoying our flow cytometry content recently? In this eBook, you’ll find a deep dive into all steps of executing a flow cytometry experiment, from reagent selection to protocols and data analysis. Download now! #FlowCytometry #Fluorescence #Antibodies #LabLife #ResearchTools #LifeSciences #ResearchMethods #CellSorting #Immunology https://lnkd.in/gNYDJF3r

"In our lab, we can modify this bacterium so that it can no longer make each piece of the capsule production machinery. Then we compare the capsule of our modified bacteria to the unmodified form of the bacteria. We believe that our findings will pave the way for drug development to dismantle the capsule production and attachment machinery, thus allowing our immune system to recognize and kill invading Klebsiella more easily." Saroj Khadka, a Ph.D. candidate in the Medical Microbiology and Immunology Track of our Biomedical Science Program, wrote a column in the Toledo Blade discussing his research on bacteria Klebsiella and its attempts to evade our immune system. Saroj is conducting his research in the laboratory of Dr. Laura Mike. Read the article: https://buff.ly/3ujTs7J #UToledoMed #research